Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis

Brattås, Marte Karen; Lilleeng, Kyrre; Hovland, Randi; Lægreid, Ingvild Jenssen; Vorland, Marta; Leh, Friedemann; Bruserud, Øystein; Gjertsen, Bjørn Tore; Reikvam, Håkon

doi:10.1186/s40364-018-0147-6

Biomarker Research

Table 1 Clinical features of previously published patients with the e6a2 transcripts

From: Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis

Age/Sex	Disease	Transcripts	Treatment	Response to TKI	Clinical course/outcome	References
80/M	Secondary AML	e6a2	Dasatinib, Imatinib	Reduction in BCR-ABL1 transcripts	Death from pancreatic tumor	Brattås et al., present
50/M	Chronic phase CML	e6a2	α interferon, Cytarabine	Not reported	Not reported	[29]
57/M	Chronic phase CML	e6a2	Imatinib, Dasatinib	Minimal cytogenetic response	Not reported	[30]
53/F	De novo AML	e6a2	Anthracycline based chemotherapy, Dasatinib, Imatinib	Complete molecular response	Not reported	[31]
76/M	Chronic phase CML	e6a2	Hydroxyurea, α interferon	Not reported	Death from cerebral ictus	[32]
65/M	Blast phase CML	e6a2	Hydroxyurea, Imatinib	Reduction of WBC after 30 days	Death from pneumonia	[33]
41/M	Chronic phase CML	e6a2	Hydroxyurea, Irradiation	Not reported	Death from sepsis 16 days after ASCT	[34]
55/F	De novo AML	e6a2	ASCT, Imatinib, Dasatinib, Nilotinib	Reduction of BCR-ABL1 transcripts	Complete molecular remission	[35]
48/F	Blast crisis CML	e6a2	Imatinib	Reduction of BCR-ABL1 transcripts	Complete molecular remission	[36]
67/M	Chronic phase CML	e6a2	Imatinib	Complete hematologic and cytogenetic response	Hematologic remission	[37]
37/M	Chronic phase CML	e6a1, e1a2	Imatinib	Partial molecular response	Disease stabilized on imatinib	[38]
48/M	Chronic phase CML	e6a2	Imatinib, Hydroxyurea, Dasatinib	Disease progression and resistance mutations	Death from blast crisis	[39]
42/M	Accelerated phase CML	e6a2	Imatinib, Dasatinib, ASCT	Persistent disease	Developed myeloid sarcoma	[40]
36/M	Chronic phase CML	e6a2, e1a2	Imatinib, Nilotinib, ASCT	Imatinib, Nilotinib	Progression to acute phase Complete cytogenetic remission	[41]
64/F	CMML	e6a2	Imatinib	Reduction of BCR-ABL1 transcripts	Not reported	[42]
Not reported	CMML	e6a2	Induction chemotherapy, Dasatinib, Nilotinib	Disease progression despite reduction of Ph + clone	Death due to disease progression	[43]
Not reported	Blast crisis CML	e6a2	Dasatinib	Reduction of BCR-ABL1 transcripts	Not reported	[44]
77/F	Accelerated phase CML	e6a2	Imatinib, Nilotinib	Complete hematological and cytogenetic response	Disease stabilized on nilotinib	[45]
53/F	De novo AML	e6a2	Imatinib, Dasatinib, ASCT	Complete hematological and cytogenetic response	Disease stabilized on dasatitinib	[46]
51/M	Accelerated phase CML	e6a2	Hydroxyurea, Imatinib, ASCT	Persistent disease	Not evidence of BCR-ABL1 transcripts day + 30 after the second transplant	[47]
43/M	CML	e6a2	Imatinib	Complete hematological and cytogenetic response	Not reported	[48]

Abbreviations: AML acute myeloid leukemia, ASCT allogenic stem cell transplantation, CML chronic myeloid leukemia, CMML chronic myelomonocytic leukemia, CMR complete molecular response, F Female, M Male, TKI tyrosine kinase inhibitors, WBC white blood cells

Back to article page

ISSN: 2050-7771

Contact us

General enquiries: journalsubmissions@springernature.com